Academic Journal
Ranolazine - a new drug for patients with recurrentantiarrhythmic therapy-refractory ventricular arrhythmias? ; Ranolazyna - nowy lek w nawracających opornych na leczenie arytmiach komorowych?
| العنوان: | Ranolazine - a new drug for patients with recurrentantiarrhythmic therapy-refractory ventricular arrhythmias? ; Ranolazyna - nowy lek w nawracających opornych na leczenie arytmiach komorowych? |
|---|---|
| المؤلفون: | Kusz, Błażej, Filipecki, Artur, Kwaśniewski, Wojciech, Orszulak, Witold, Urbańczyk-Świć, Dagmara, Chmiel, Artur, Swinarew, Andrzej S., Szydło, Krzysztof, Mizia-Stec, Katarzyna |
| سنة النشر: | 2019 |
| المجموعة: | The Repository of the University of Silesia (RE-BUŚ) / Repozytorium Uniwersytetu Śląskiego |
| مصطلحات موضوعية: | Ranolazine, Ventricular arrhythmias |
| الوصف: | Introduction. The pharmacological treatment of ventricular arrhythmias (VA) has significant limitations. Ranolazine is a relatively new drug with documented antianginal and anti-ischaemic mechanisms and where preclinical data provides evidence of additional antiarrhythmic properties. The aim of this article was to evaluate the safety and efficacy of ranolazine in patients with recurrent antiarrhythmic therapy-refractory VA. Material and methods. This prospective evaluation included 30 patients (pts) (male/female: 26/4; mean age: 65 ± 10 years; coronary artery disease/dilated cardiomyopathy: 20/10; New York Heart Association class I/II/III/IV: 2/14/12/2, left ventricular ejection fraction: 27 ± 10%; implantable cardioverter-defibrillator (ICD): 15 pts, implantable cardioverter-defibrillator with cardiac resynchronisation therapy (CRT-D): 14 pts with recurrent significant VA [ventricular fibrillation, sustained ventricular tachycardia (VT) and/or non-sustained VT, multiple ventricular premature complexes > 1,000//day, biventricular stimulation (BiV) < 95%] and where standard treatment options, i.e. pharmacotherapy, coronary revascularisation, and percutaneous ablation, had proved ineffective. The severity of the arrhythmia was assessed by 24-hour electrocardiographic (ECG) Holter monitoring and in ICD/CRT-D memory recording. The patients received, in addition to the standard pharmacotherapy amiodarone: 18 pts, beta-blocker: 26 pts) ranolazine 375 mg twice daily for three months. Baseline data was compared to the data obtained after the three months of ranolazine treatment. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2353-7760 2353-7752 |
| Relation: | "Folia Cardiologica" 2019, nr 2, s. 150-155; http://hdl.handle.net/20.500.12128/12332 |
| DOI: | 10.5603/FC.2019.0019 |
| الاتاحة: | https://hdl.handle.net/20.500.12128/12332 https://doi.org/10.5603/FC.2019.0019 |
| Rights: | Uznanie autorstwa-Użycie niekomercyjne-Bez utworów zależnych 3.0 Polska ; http://creativecommons.org/licenses/by-nc-nd/3.0/pl/ |
| رقم الانضمام: | edsbas.B7B1152C |
| قاعدة البيانات: | BASE |
| تدمد: | 23537760 23537752 |
|---|---|
| DOI: | 10.5603/FC.2019.0019 |